



Ferumoxsil

Revised: February 7, 2019.

CASRN: 171544-35-7

Drug Levels and Effects

Summary of Use during Lactation

Ferumoxsil is not approved for marketing in the United States by the U.S. Food and Drug Administration. No information is available on the clinical use of ferumoxsil during breastfeeding. If ferumoxsil is required by the mother, it is not a reason to discontinue breastfeeding.[1] However, since there is no published experience with ferumoxsil during breastfeeding, other agents may be preferred, especially while nursing a newborn or preterm infant.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

References

1. Cova MA, Stacul F, Quaranta R et al. Radiological contrast media in the breastfeeding woman: a position paper of the Italian Society of Radiology (SIRM), the Italian Society of Paediatrics (SIP), the Italian Society of Neonatology (SIN) and the Task Force on Breastfeeding, Ministry of Health, Italy. *Eur Radiol.* 2014;24:2012-22. PubMed PMID: 24838733.

Substance Identification

Substance Name

Ferumoxsil

CAS Registry Number

171544-35-7

Drug Class

Breast Feeding

Lactation

Contrast Media

Diagnostic Agents